Catalyst Wire Dossier Catalyst Wire Dossier

DB107-Retroviral Replicating Vector (RRV)

DB107-Retroviral Replicating Vector
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for DB107-Retroviral Replicating Vector (RRV), covering 2025-05-29 to 2025-05-29. Get the full timeline:

Most recent: Clinical Trial Update: DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma [Phase 2]

See pricing